1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Cannabinoid Derived Pharmaceutical by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Cannabinoid Derived Pharmaceutical by Country/Region, 2018, 2022 & 2029
2.2 Cannabinoid Derived Pharmaceutical Segment by Type
2.2.1 Cannabinoid Receptor Type 1 (CB1)
2.2.2 Cannabinoid Receptor Type 2 (CB2)
2.2.3 Others
2.3 Cannabinoid Derived Pharmaceutical Sales by Type
2.3.1 Global Cannabinoid Derived Pharmaceutical Sales Market Share by Type (2018-2023)
2.3.2 Global Cannabinoid Derived Pharmaceutical Revenue and Market Share by Type (2018-2023)
2.3.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Type (2018-2023)
2.4 Cannabinoid Derived Pharmaceutical Segment by Application
2.4.1 Epilepsy
2.4.2 Migraine
2.4.3 Multiple Sclerosis
2.4.4 Others
2.5 Cannabinoid Derived Pharmaceutical Sales by Application
2.5.1 Global Cannabinoid Derived Pharmaceutical Sale Market Share by Application (2018-2023)
2.5.2 Global Cannabinoid Derived Pharmaceutical Revenue and Market Share by Application (2018-2023)
2.5.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Application (2018-2023)
3 Global Cannabinoid Derived Pharmaceutical by Company
3.1 Global Cannabinoid Derived Pharmaceutical Breakdown Data by Company
3.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Company (2018-2023)
3.1.2 Global Cannabinoid Derived Pharmaceutical Sales Market Share by Company (2018-2023)
3.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Company (2018-2023)
3.2.1 Global Cannabinoid Derived Pharmaceutical Revenue by Company (2018-2023)
3.2.2 Global Cannabinoid Derived Pharmaceutical Revenue Market Share by Company (2018-2023)
3.3 Global Cannabinoid Derived Pharmaceutical Sale Price by Company
3.4 Key Manufacturers Cannabinoid Derived Pharmaceutical Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cannabinoid Derived Pharmaceutical Product Location Distribution
3.4.2 Players Cannabinoid Derived Pharmaceutical Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cannabinoid Derived Pharmaceutical by Geographic Region
4.1 World Historic Cannabinoid Derived Pharmaceutical Market Size by Geographic Region (2018-2023)
4.1.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Cannabinoid Derived Pharmaceutical Market Size by Country/Region (2018-2023)
4.2.1 Global Cannabinoid Derived Pharmaceutical Annual Sales by Country/Region (2018-2023)
4.2.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue by Country/Region (2018-2023)
4.3 Americas Cannabinoid Derived Pharmaceutical Sales Growth
4.4 APAC Cannabinoid Derived Pharmaceutical Sales Growth
4.5 Europe Cannabinoid Derived Pharmaceutical Sales Growth
4.6 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales Growth
5 Americas
5.1 Americas Cannabinoid Derived Pharmaceutical Sales by Country
5.1.1 Americas Cannabinoid Derived Pharmaceutical Sales by Country (2018-2023)
5.1.2 Americas Cannabinoid Derived Pharmaceutical Revenue by Country (2018-2023)
5.2 Americas Cannabinoid Derived Pharmaceutical Sales by Type
5.3 Americas Cannabinoid Derived Pharmaceutical Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cannabinoid Derived Pharmaceutical Sales by Region
6.1.1 APAC Cannabinoid Derived Pharmaceutical Sales by Region (2018-2023)
6.1.2 APAC Cannabinoid Derived Pharmaceutical Revenue by Region (2018-2023)
6.2 APAC Cannabinoid Derived Pharmaceutical Sales by Type
6.3 APAC Cannabinoid Derived Pharmaceutical Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cannabinoid Derived Pharmaceutical by Country
7.1.1 Europe Cannabinoid Derived Pharmaceutical Sales by Country (2018-2023)
7.1.2 Europe Cannabinoid Derived Pharmaceutical Revenue by Country (2018-2023)
7.2 Europe Cannabinoid Derived Pharmaceutical Sales by Type
7.3 Europe Cannabinoid Derived Pharmaceutical Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cannabinoid Derived Pharmaceutical by Country
8.1.1 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Country (2018-2023)
8.1.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Revenue by Country (2018-2023)
8.2 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Type
8.3 Middle East & Africa Cannabinoid Derived Pharmaceutical Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cannabinoid Derived Pharmaceutical
10.3 Manufacturing Process Analysis of Cannabinoid Derived Pharmaceutical
10.4 Industry Chain Structure of Cannabinoid Derived Pharmaceutical
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cannabinoid Derived Pharmaceutical Distributors
11.3 Cannabinoid Derived Pharmaceutical Customer
12 World Forecast Review for Cannabinoid Derived Pharmaceutical by Geographic Region
12.1 Global Cannabinoid Derived Pharmaceutical Market Size Forecast by Region
12.1.1 Global Cannabinoid Derived Pharmaceutical Forecast by Region (2024-2029)
12.1.2 Global Cannabinoid Derived Pharmaceutical Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cannabinoid Derived Pharmaceutical Forecast by Type
12.7 Global Cannabinoid Derived Pharmaceutical Forecast by Application
13 Key Players Analysis
13.1 Cara Therapeutics Inc
13.1.1 Cara Therapeutics Inc Company Information
13.1.2 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.1.3 Cara Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Cara Therapeutics Inc Main Business Overview
13.1.5 Cara Therapeutics Inc Latest Developments
13.2 Arena Pharmaceuticals
13.2.1 Arena Pharmaceuticals Company Information
13.2.2 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.2.3 Arena Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Arena Pharmaceuticals Main Business Overview
13.2.5 Arena Pharmaceuticals Latest Developments
13.3 Cannabics Pharmaceuticals Inc
13.3.1 Cannabics Pharmaceuticals Inc Company Information
13.3.2 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.3.3 Cannabics Pharmaceuticals Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Cannabics Pharmaceuticals Inc Main Business Overview
13.3.5 Cannabics Pharmaceuticals Inc Latest Developments
13.4 Echo Pharmaceuticals
13.4.1 Echo Pharmaceuticals Company Information
13.4.2 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.4.3 Echo Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Echo Pharmaceuticals Main Business Overview
13.4.5 Echo Pharmaceuticals Latest Developments
13.5 Gw Pharmaceuticals
13.5.1 Gw Pharmaceuticals Company Information
13.5.2 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.5.3 Gw Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Gw Pharmaceuticals Main Business Overview
13.5.5 Gw Pharmaceuticals Latest Developments
13.6 Inmed Pharmaceuticals
13.6.1 Inmed Pharmaceuticals Company Information
13.6.2 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.6.3 Inmed Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Inmed Pharmaceuticals Main Business Overview
13.6.5 Inmed Pharmaceuticals Latest Developments
13.7 Insys Therapeutics Inc
13.7.1 Insys Therapeutics Inc Company Information
13.7.2 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.7.3 Insys Therapeutics Inc Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Insys Therapeutics Inc Main Business Overview
13.7.5 Insys Therapeutics Inc Latest Developments
13.8 Larapharm
13.8.1 Larapharm Company Information
13.8.2 Larapharm Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.8.3 Larapharm Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Larapharm Main Business Overview
13.8.5 Larapharm Latest Developments
13.9 Mgc Pharmaceuticals Ltd
13.9.1 Mgc Pharmaceuticals Ltd Company Information
13.9.2 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.9.3 Mgc Pharmaceuticals Ltd Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Mgc Pharmaceuticals Ltd Main Business Overview
13.9.5 Mgc Pharmaceuticals Ltd Latest Developments
13.10 One World Cannabis
13.10.1 One World Cannabis Company Information
13.10.2 One World Cannabis Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.10.3 One World Cannabis Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 One World Cannabis Main Business Overview
13.10.5 One World Cannabis Latest Developments
13.11 Orpheus Medica
13.11.1 Orpheus Medica Company Information
13.11.2 Orpheus Medica Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.11.3 Orpheus Medica Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Orpheus Medica Main Business Overview
13.11.5 Orpheus Medica Latest Developments
13.12 Receptor Life Sciences
13.12.1 Receptor Life Sciences Company Information
13.12.2 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.12.3 Receptor Life Sciences Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Receptor Life Sciences Main Business Overview
13.12.5 Receptor Life Sciences Latest Developments
13.13 Respirerx Pharmaceuticals
13.13.1 Respirerx Pharmaceuticals Company Information
13.13.2 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.13.3 Respirerx Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Respirerx Pharmaceuticals Main Business Overview
13.13.5 Respirerx Pharmaceuticals Latest Developments
13.14 Tetra Bio-Pharma
13.14.1 Tetra Bio-Pharma Company Information
13.14.2 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.14.3 Tetra Bio-Pharma Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Tetra Bio-Pharma Main Business Overview
13.14.5 Tetra Bio-Pharma Latest Developments
13.15 Cardiol Therapeutics
13.15.1 Cardiol Therapeutics Company Information
13.15.2 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.15.3 Cardiol Therapeutics Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Cardiol Therapeutics Main Business Overview
13.15.5 Cardiol Therapeutics Latest Developments
13.16 United Cannabis Corporation
13.16.1 United Cannabis Corporation Company Information
13.16.2 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.16.3 United Cannabis Corporation Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 United Cannabis Corporation Main Business Overview
13.16.5 United Cannabis Corporation Latest Developments
13.17 Zynerba Pharmaceuticals
13.17.1 Zynerba Pharmaceuticals Company Information
13.17.2 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Product Portfolios and Specifications
13.17.3 Zynerba Pharmaceuticals Cannabinoid Derived Pharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Zynerba Pharmaceuticals Main Business Overview
13.17.5 Zynerba Pharmaceuticals Latest Developments
14 Research Findings and Conclusion
| ※参考情報 カンナビノイド由来医薬品は、カンナビノイドと呼ばれる化合物を基にした薬剤であり、主に大麻植物から抽出される成分やその合成物が使用されています。カンナビノイドは、食品や医薬品の用途において注目を集めており、特にその医療効果が多くの研究や臨床試験において探求されています。 カンナビノイドは、主に植物性カンナビノイドと合成カンナビノイドに分類されます。植物性カンナビノイドは、大麻植物に自然に存在するもので、テトラヒドロカンナビノール（THC）やカンナビジオール（CBD）が代表的な成分です。THCは主に精神活性作用を持ち、嗜好品としての用途が広く知られています。一方でCBDは精神作用がなく、抗炎症作用やストレス軽減、てんかんの治療に使用されることが多くなっています。 合成カンナビノイドは、化学的手法によって人工的に生産されたカンナビノイドです。これらは、植物由来のカンナビノイドと同様の受容体に作用しますが、より強力な効果を持つ場合があります。合成カンナビノイドは、特に研究や治療において特定の機能を持たせるために開発されますが、その安全性と副作用については慎重な検討が必要です。 カンナビノイド由来医薬品の特徴の一つは、高い生物学的利用能です。これは、カンナビノイドが体内のカンナビノイド受容体に結合し、様々な生理作用を引き起こすためです。カンナビノイドは、主に脳や免疫系、消化器系に存在する特定の受容体に作用し、感情や痛みの調節、食欲のコントロール、炎症反応の抑制を可能にします。そのため、医療分野でのカンナビノイドの利用が進んでいます。 医療用途としては、慢性痛の管理、がん治療に伴う吐き気の緩和、神経障害性疼痛の治療、てんかん患者の発作抑制、さらには不安障害やうつ病の治療などが挙げられます。また、最近では神経変性疾患への応用も期待されています。これにより、カンナビノイド由来医薬品は、副作用が少ない治療選択肢として注目されています。 また、カンナビノイド由来医薬品の開発には、さまざまな関連技術が利用されています。天然のカンナビノイドを抽出するための過程や、合成カンナビノイドの設計や生成、さらにはこれらの効果を高めるための製剤技術が重要です。特に、ドラッグデリバリーシステムの改良が進んでおり、皮膚からの経皮吸収、吸入、経口投与など、患者に適切な投与方法が研究されています。 さらに、最近の医薬品開発は、個々の患者の遺伝的背景や生理学的特性に基づいたパーソナライズドメディスンの方向に進んでいます。カンナビノイドの効果は個人によって異なるため、患者ごとの特性に合わせた治療が検討されています。これにより、副作用を軽減し、効果的な治療を行うことができます。 現在、カンナビノイド由来医薬品は、多くの国で医療目的で使用が認可されており、これに伴って規制や法律も急速に進化しています。特に、カンナビノイドの合法化が進む中、研究と臨床試験が加速されています。しかし、依然として多くの国や地域では規制が厳しく、研究の自由度に制限がかかる場合もあります。さらなる科学的データとエビデンスが求められている状況です。 危険性についても触れておく必要があります。カンナビノイドに対する依存症や、精神的な副作用が懸念されることもあります。このため、医薬品としての利用においては、医師との適切な相談が不可欠です。また、市場には品質や安全性が保証されていない製品も存在するため、選択には十分な注意が必要です。 まとめると、カンナビノイド由来医薬品はその生理活性や多様な医療効果により、特に慢性疾患や神経疾患に対する新たな治療法としての可能性を持つことが期待されています。しかし、その効果と安全性のバランスを考慮し、適切な研究と医療体制の整備が進められる必要があります。今後もカンナビノイド由来医薬品の研究は続くと考えられ、より安全で効果的な治療法が見つかることを期待しています。 |
